San Franciso, CANCT06066502Now EnrollingIRB Ready

Acute Respiratory Distress Syndrome Clinical Trial in San Franciso, CA

Access cutting-edge acute respiratory distress syndrome treatment through this phase 3 clinical trial at a research site in San Franciso. Study-provided care at no cost to qualified participants.

Sponsored by Beth Israel Deaconess Medical Center

Quick Self-Assessment

See if you qualify for this San Franciso location

Preparing your pre-screening questions…

Expert Care in San Franciso

Access acute respiratory distress syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute respiratory distress syndrome treatment provided free

Apply for This San Franciso Location

Check if you qualify for this acute respiratory distress syndrome clinical trial in San Franciso, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Franciso

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Franciso site if eligible
  4. 4Begin participation

About This Acute Respiratory Distress Syndrome Study in San Franciso

The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.

Sponsor: Beth Israel Deaconess Medical Center

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
Ventilator-dependent ARDS, with all of the following (a-e):
Invasive ventilation with positive end-expiratory pressure (PEEP) ≥ 8 cm H2O or FiO2 ≥ 0.5
Hypoxemia as characterized by: • If arterial blood gas (ABG) available: the partial pressure of oxygen in the arterial blood (PaO2)/FiO2 ≤ 300 mm Hg, or, • if ABG not available OR overt clinical deterioration in oxygenation since last ABG: SpO2/FiO2 ≤ 316 with SpO2 ≤ 97% (both conditions) on two representative assessments between 1 to 6 hours apart. • If patient is positioned prone or receiving inhaled pulmonary vasodilator at time of screening: Qualifying PaO2/FiO2 or SpO2/FiO2 (as defined above) that was recorded within the 6 hours immediately prior to initiating either of these therapies may be used for eligibility determination. • If PEEP has been increased by \> 5 cm H2O within the last 12 hours immediately prior to screening: Qualifying PaO2/FiO2 or SpO2/FiO2 (as defined above) prior to PEEP increase may be used for eligibility determination if recorded within this 12-hour window.
Bilateral lung opacities on chest imaging not fully explained by effusions, lobar collapse, or nodules
Respiratory failure not fully explained by heart failure or fluid overload
Onset within 1 week of clinical insult or new/worsening symptoms
Early in ARDS course
Full criteria for ARDS (#2 above) first met within previous 3 days
Current invasive ventilation episode not more than 4 days duration
Current severe hypoxemic episode (receipt of invasive ventilation, noninvasive ventilation, or high-flow nasal cannula) not more than 10 days duration

Exclusion Criteria

Esophageal manometry already in use clinically
Severe brain injury: including suspected elevated intracranial pressure, cerebral edema, or Glasgow coma score (GCS) ≤ 8 directly caused by severe brain injury (e.g., ischemia or hemorrhage)
Gross barotrauma or chest tube inserted to treat barotrauma (note: chest tube inserted strictly for drainage of pleural effusion is not an exclusion)
Esophageal pathology that, in judgement of the site investigator, significantly increases risk of esophageal catheter placement, including high-risk esophageal varices, recent oropharyngeal or gastroesophageal surgery; or past esophagectomy
Ongoing severe coagulopathy (platelet \< 5000/μL or INR \> 4)
Extracorporeal membrane oxygenation (ECMO) or CO2 removal (ECCO2R)
Neuromuscular disease that impairs spontaneous breathing (including but not limited to amyotrophic lateral sclerosis, Guillain-Barré syndrome, spinal cord injury at C5 or above)
Any of the following severe chronic lung diseases: cystic fibrosis, acute bronchiectasis exacerbation, acute exacerbation of a chronic interstitial lung disease (ILD), chronic pulmonary hypertension (PH) on PH-targeted vasoactive medication, or lung transplant
End-stage chronic cirrhosis with Child-Pugh Class C (Section 12.3)
ICU admission for burn injury
Current ICU stay \> 2 weeks or acute care hospital stay \> 4 weeks
Moribund patient not expected to survive 24 hours as assessed by the study physician; if cardiopulmonary resuscitation (CPR) was provided, assessment for moribund status must occur at least 6 hours after CPR was completed
Current limitation on life-sustaining care (other than do-not-resuscitate), or expectation by clinical team that a limitation on life-sustained care will be adopted within next 24 hours.
Treating clinician refusal or unwilling to use protocol-specified ventilator settings/modes
Previous enrollment in this trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Franciso?

Yes, this clinical trial (NCT06066502) has an active research site in San Franciso, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Respiratory Distress Syndrome Treatment Options in San Franciso, CA

If you're searching for acute respiratory distress syndrome treatment options in San Franciso, CA, this clinical trial (NCT06066502) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Franciso research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced acute respiratory distress syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute respiratory distress syndrome clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in San Franciso, CA

See all rheumatoid arthritis clinical trials recruiting in San Franciso — not just this study.

Browse Rheumatoid Arthritis Trials in San Franciso →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Franciso?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Franciso, CA